X-Linked Hypophosphatemia Companies | Market Research Future

Top Industry Leaders in the X-Linked Hypophosphatemia Market

X-Linked Hypophosphatemia Key Companies Latest X-Linked Hypophosphatemia Companies Update

July 2022: Ultragenyx Pharmaceutical Inc., a biopharmaceutical company specializing in the development and commercialization of innovative products for severe rare and ultra-rare genetic disorders, announced today the $500 million acquisition by OMERS, one of Canada's largest defined benefit pension plans, of 30% of the company's royalty interest from Kyowa Kirin Co., Ltd on future sales of Crysvita (burosumab) in the United States (U.S.) and Canada. The royalty payment entitlement of OMERS is contingent upon the product's net sales commencing in April 2023. The maximum allowable payment is 1.45 times the purchase price. Crysvita has amassed net sales in excess of $1.3 billion during its initial four years of availability in North America, positioning it as one of the most prosperous product introductions within the rare disease sector. By means of this non-dilutive financing, Ultragenyx strengthens its balance sheet, provides funds for the continuous commercialization of numerous approved medications, and advances its diversified clinical pipeline.

Kyowa Kirin, Inc., a subsidiary of the Japanese-based global specialty pharmaceutical company Kyowa Kirin Co., Ltd., will present novel findings in October 2023 that enhance knowledge regarding the clinical attributes and real-life experiences of children, adolescents, and adults afflicted with X-linked hypophosphatemia (XLH), an uncommon genetic metabolic bone disease. Those who have XLH are confronted with the perpetual challenge of disease management and progressively deteriorating morbidities, both of which have detrimental effects on their quality of life. A rare, chronic genetic disorder, X-linked hypophosphatemia can affect the muscles and bones of both infants and adults. In people with XLH, there is insufficient phosphorus storage in the body, an essential mineral for bone health. As a result of the overproduction of fibroblast growth factor 23 (FGF23), an excessive amount of phosphorus is excreted via the urine.

List of X-Linked Hypophosphatemia Key companies in the market